0001209191-23-043304.txt : 20230725 0001209191-23-043304.hdr.sgml : 20230725 20230725162318 ACCESSION NUMBER: 0001209191-23-043304 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230721 FILED AS OF DATE: 20230725 DATE AS OF CHANGE: 20230725 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Goldenberg Gary CENTRAL INDEX KEY: 0001741938 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38529 FILM NUMBER: 231108814 MAIL ADDRESS: STREET 1: C/O VERRICA PHARMACEUTICALS INC. STREET 2: 10 NORTH HIGH STREET, SUITE 200 CITY: WEST CHESTER STATE: PA ZIP: 19380 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Verrica Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001660334 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 463137900 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10 NORTH HIGH STREET STREET 2: SUITE 200 CITY: WEST CHESTER STATE: PA ZIP: 19380 BUSINESS PHONE: 484-453-3300 MAIL ADDRESS: STREET 1: 10 NORTH HIGH STREET STREET 2: SUITE 200 CITY: WEST CHESTER STATE: PA ZIP: 19380 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-07-21 0 0001660334 Verrica Pharmaceuticals Inc. VRCA 0001741938 Goldenberg Gary C/O VERRICA PHARMACEUTICALS INC. 44 WEST GAY STREET, SUITE 400 WEST CHESTER PA 19380 0 1 0 0 Chief Medical Officer 0 Common Stock 2023-07-21 4 A 0 75000 0.00 A 98809 D Common Stock 2023-07-24 4 S 0 28699 4.83 D 70110 D Represents restricted stock unit ("RSU") awards with performance based vesting, which were originally granted in 2020. The RSUs vested 50% upon receipt of regulatory approval of the Issuer's new drug application for VP-102 for the treatment of molluscum, and the remaining 50% shall vest on July 21, 2024, subject to the Reporting Person's continuous service through each applicable date. Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on July 21, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.75 to $4.955 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Mark Ballantyne, Attorney-in-Fact 2023-07-25